KPV Overview
Category:
Tripeptide (α-MSH C-terminal fragment)
How it works:
Derived from α-melanocyte stimulating hormone (α-MSH), KPV exerts anti-inflammatory effects by inhibiting NF-κB and related pro-inflammatory signaling, can be taken up into epithelial/immune cells via the PepT1 transporter, and acts via both receptor-dependent and independent mechanisms in different tissues.
Alternative names:
KPV, Lys-Pro-Val, α-MSH(11–13) fragment (C-terminal tripeptide)
Primary research focus:
- Intestinal inflammation / colitis models
- Cutaneous wound healing
- Mucosal protection
- Topical dermatologic uses
Potential risks:
- Mostly preclinical data; human clinical data are limited.
- Long-term systemic safety and robust randomized controlled trials are sparse.
- Delivery and stability are important for effect.
What is KPV?
KPV (Lys-Pro-Val) is a small tripeptide representing the C-terminal active portion of α-melanocyte stimulating hormone (α-MSH). It was identified as a minimal sequence that retains anti-inflammatory activity. Because it’s very small, KPV is an attractive candidate for topical, mucosal, or targeted delivery where local anti-inflammatory and reparative effects are desired.
Who might notice benefits? People or models with:
How KPV works in the body
- Inhibits NF-κB and pro-inflammatory signaling. KPV reduces nuclear translocation/activation of NF-κB in multiple cell types, lowering pro-inflammatory cytokines.
- PepT1 uptake in epithelia and immune cells. Intestinal uptake via the oligopeptide transporter PepT1 is an important route that allows KPV to reach intracellular targets in gut epithelium and immune cells.
- MC-receptor dependent and independent actions. While derived from α-MSH (which signals through melanocortin receptors), KPV’s anti-inflammatory effects can occur independently of classical MC1R signaling in some models, suggesting multiple mechanisms.
- Promotes epithelial repair. In corneal and skin models KPV enhances cell viability, migration, and re-epithelialization—accelerating wound closure.
Benefits
Reduces inflammation
KPV inhibits NF-κB activation and downregulates pro-inflammatory cytokines in vitro and in vivo. This molecular effect is central to its utility in inflammatory models (airway, gut, skin).
Protects and heals mucosa
Seminal work showed oral/rectal KPV reduces severity of chemically induced colitis in mice and that PepT1 mediates uptake into intestinal cells — improving histology, reducing cytokines, and restoring barrier function in those models. These preclinical results support KPV as a mucosal-protective agent.
Speeds wound healing & epithelial repair
Studies in corneal epithelial cells and skin wound models found KPV promotes cell viability and migration, accelerates re-epithelialization, and may involve nitric oxide pathways or other repair mediators. Advanced topical hydrogels and delivery systems further amplify these effects in preclinical studies.
Antimicrobial and barrier-support effects
Some recent formulations (KPV-loaded hydrogels, nanocarriers) show antibacterial activity and improved epithelial barrier restoration — useful in infected wounds or chemotherapy-induced mucositis models.
Flexible delivery: topical, mucosal, targeted
Because KPV is small, multiple routes (topical creams, iontophoretic or microneedle delivery, mucoadhesive hydrogels, oral/rectal dosing in animal colitis models) have been explored to improve local concentrations and therapeutic effect. Delivery choice strongly affects outcomes.
Clinical Studies
- Preclinical animal evidence is strong. The most cited human-relevant work is in mouse models of colitis (Dalmasso et al.), where KPV reduced inflammation and improved barrier function; many subsequent studies replicate anti-inflammatory and reparative effects in various tissues.
- Translational / formulation research is active. Recent years show growing interest in advanced delivery systems (mucoadhesive hydrogels, iontophoresis, microneedles, PepT1-targeted nanodrugs) to get functional KPV concentrations to target tissues. These are largely preclinical or early-stage translational studies.
- Human clinical trials: As of the sources reviewed, robust randomized controlled trials in humans are limited; much evidence is preclinical, small proof-of-concept, or formulation-focused. Larger human trials are needed to confirm efficacy, dosing, and safety in specific indications.
Safety, Side Effects, and Considerations
Reported safety profile: KPV is generally well-tolerated in preclinical models and in topical/translational studies; local application and targeted delivery show low irritation in short-term experiments. Systemic human safety data are limited.
Possible mild effects: Local irritation at application sites (topical) has been observed rarely in formulation studies. Systemic adverse events are not well characterized because human systemic studies are sparse.
Mechanistic cautions: KPV modulates inflammatory pathways and can affect immune signaling. While this is beneficial in inflammatory injury, long-term immune modulation in humans has not been extensively evaluated. Also, because PepT1 expression varies between tissues and disease states, uptake and effects can be context dependent.
Delivery matters: Efficacy depends strongly on reaching sufficient local concentration. Studies emphasize the importance of delivery systems (hydrogels, microneedles, iontophoresis, nanocarriers) to achieve therapeutic benefit without systemic exposure.
Practical notes & sourcing: Use research-grade peptides and validated formulations for experimental work. For clinical or off-label use, involve medical oversight; the field needs larger human trials to define dose, regimen, and long-term safety.
Bottom line
KPV (Lys-Pro-Val) is a small tripeptide with consistent preclinical evidence for potent anti-inflammatory and mucosal/epithelial-repair actions. The strongest data come from animal colitis models and wound/epithelial repair studies; translational work on delivery systems is advancing. Human clinical evidence is still limited, so while KPV is promising—especially for localized inflammatory and mucosal conditions—larger clinical trials are needed to confirm efficacy, optimal delivery, dose, and long-term safety.
